Milk-derived exosomes for oral delivery of paclitaxel

Rowinsky, 1995, Paclitaxel (taxol), N Engl J Med, 332, 1004, 10.1056/NEJM199504133321507

Gelderblom, 2001, Cremophor EL: the drawbacks and advantages of vehicle selection for drug formulation, Eur J Cancer, 37, 1590, 10.1016/S0959-8049(01)00171-X

Sparreboom, 2005, Comparative preclinical and clinical pharmacokinetics of a cremophor-free, nanoparticle albumin-bound paclitaxel (ABI-007) and paclitaxel formulated in cremophor (Taxol), Clin Cancer Res, 11, 4136, 10.1158/1078-0432.CCR-04-2291

Gradishar, 2005, Phase III trial of nanoparticle albumin-bound paclitaxel compared with polyethylated castor oil-based paclitaxel in women with breast cancer, J Clin Oncol, 23, 7794, 10.1200/JCO.2005.04.937

Bawarski, 2008, Emerging nanopharmaceuticals, Nanomedicine, 4, 273, 10.1016/j.nano.2008.06.002

Aisner, 2007, Overview of the changing paradigm in cancer treatment: oral chemotherapy, Am J Health, 64, S4

Joo, 2008, Oral paclitaxel chemotherapy for brain tumors: ideal combination treatment of paclitaxel and P-glycoprotein inhibitor, Oncol Rep, 19, 17

Torne, 2010, Enhanced oral paclitaxel bioavailability after administration of paclitaxel-loaded nanosponges, Drug Deliv, 17, 419, 10.3109/10717541003777233

Ma, 2013, Paclitaxel nano-delivery systems: a comprehensive review, J Nanomed Nanotechol, 4, 1000164, 10.4172/2157-7439.1000164

Munagala, 2016, Bovine milk-derived exosomes for drug delivery, Cancer Lett, 371, 48, 10.1016/j.canlet.2015.10.020

Kim, 2016, Development of exosome-encapsulated paclitaxel to overcome MDR in cancer cells, Nanomedicine, 12, 655, 10.1016/j.nano.2015.10.012

Izumi, 2012, Bovine milk contains microRNA and messenger RNA that are stable under degradative conditions, J Dairy Sci, 95, 4831, 10.3168/jds.2012-5489

Aqil, 2016, Exosomal formulation enhances therapeutic response of celastrol against lung cancer, Exp Mol Pathol, 101, 12, 10.1016/j.yexmp.2016.05.013

Marques, 2011, Simulated biological fluids with possible application in dissolution testing, Dissolut Technol, 18, 15, 10.14227/DT180311P15

Estrella, 2013, Acidity generated by the tumor microenvironment drives local invasion, Cancer Res, 73, 1524, 10.1158/0008-5472.CAN-12-2796

Yang, 2007, Enhanced solubility and stability of PEGylated liposomal paclitaxel: in vitro and in vivo evaluation, Int J Pharm, 338, 317, 10.1016/j.ijpharm.2007.02.011

Koziara, 2004, Paclitaxel nanoparticles for the potential treatment of brain tumors, J Control Release, 99, 259, 10.1016/j.jconrel.2004.07.006

Fernandez, 2008, Successful mobilization of hematopoietic peripheral blood progenitor cells with paclitaxel-based chemotherapy as initial or salvage regimen in patients with hematologic malignancies, Haematologica, 93, 1436, 10.3324/haematol.13056

Shea, 1997, Mobilization of peripheral blood progenitor cells with paclitaxel-based chemotherapy, Semin Oncol

Perera, 1996, Paclitaxel (Taxol)-induced NF-kappaB translocation in murine macrophages, Infect Immun, 64, 878, 10.1128/IAI.64.3.878-884.1996

Malingre, 2001, Oral delivery of taxanes, Invest New Drugs, 19, 155, 10.1023/A:1010635000879

Lee, 2003, Hydrotropic solubilization of paclitaxel: analysis of chemical structures for hydrotropic property, Pharm Res, 20, 1022, 10.1023/A:1024458206032

Konno, 2003, Enhanced solubility of paclitaxel using water-soluble and biocompatible 2-methacryloyloxyethyl phosphorylcholine polymers, J Biomed Mater Res A, 65, 209, 10.1002/jbm.a.10481

Beijnen, 1994, Bioanalysis, pharmacokinetics, and pharmacodynamics of the novel anticancer drug paclitaxel (Taxol), Semin Oncol

Joshi, 2013, Carboxymethyl-chitosan-tethered lipid vesicles: hybrid nanoblanket for oral delivery of paclitaxel, Biomacromolecules, 14, 2272, 10.1021/bm400406x

Jain, 2012, Polyelectrolyte stabilized multilayered liposomes for oral delivery of paclitaxel, Biomaterials, 33, 6758, 10.1016/j.biomaterials.2012.05.026

Calleja, 2015, Controlled release, intestinal transport, and oral bioavailablity of paclitaxel can be considerably increased using suitably tailored pegylated poly(anhydride) nanoparticles, J Pharm Sci, 104, 2877, 10.1002/jps.24354

Bothiraja, 2014, Chitosan coated layered clay montmorillonite nanocomposites modulate oral delivery of paclitaxel in colonic cancer, Mater Technol, 29, B120, 10.1179/1753555714Y.0000000174

Bhardwaj, 2009, PLGA nanoparticles stabilized with cationic surfactant: safety studies and application in oral delivery of paclitaxel to treat chemical-induced breast cancer in rat, Pharm Res, 26, 2495, 10.1007/s11095-009-9965-4

Peltier, 2006, Enhanced oral paclitaxel bioavailability after administration of paclitaxel-loaded lipid nanocapsules, Pharm Res, 23, 1243, 10.1007/s11095-006-0022-2

Pandita, 2011, Development of lipid-based nanoparticles for enhancing the oral bioavailability of paclitaxel, AAPS PharmSciTech, 12, 712, 10.1208/s12249-011-9636-8

Tiwari, 2006, Improved oral delivery of paclitaxel following administration in nanoemulsion formulations, J Nanosci Nanotechnol, 6, 3215, 10.1166/jnn.2006.440

Ganta, 2009, Coadministration of paclitaxel and curcumin in nanoemulsion formulations to overcome multidrug resistance in tumor cells, Mol Pharm, 6, 928, 10.1021/mp800240j

Agrawal, 2014, Improved stability and antidiabetic potential of insulin containing folic acid functionalized polymer stabilized multilayered liposomes following oral administration, Biomacromolecules, 15, 350, 10.1021/bm401580k

Hoque, 2013, Oleic acid may be the key contributor in the BAMLET-induced erythrocyte hemolysis and tumoricidal action, PLoS One, 8, e68390, 10.1371/journal.pone.0068390

Liskova, 2010, Effect of denaturation of alpha-lactalbumin on the formation of BAMLET (bovine alpha-lactalbumin made lethal to tumor cells), J Agric Food Chem, 58, 4421, 10.1021/jf903901j

Rammer, 2010, BAMLET activates a lysosomal cell death program in cancer cells, Mol Cancer Ther, 9, 24, 10.1158/1535-7163.MCT-09-0559

Kreuter, 1991, Peroral administration of nanoparticles, Adv Drug Deliver Rev, 7, 71, 10.1016/0169-409X(91)90048-H